AI Software for X-Rays Gets FDA De Novo Classification for Bone Mineral Density Screening
Leveraging artificial intelligence, the Rho software assessment of X-rays may allow earlier detection of bone loss.
The Food and Drug Administration (FDA) has granted a De Novo classification to Rho™, an artificial intelligence (AI) software that may facilitate bone loss detection through opportunistic screening of X-rays for low bone mineral density (BMD).
Noting that less pronounced bone loss is more difficult for radiologists to assess via standard X-rays, 16 Bit, the manufacturer of the Rho software, said adjunctive use of Rho can be a viable alternative. Offering automated scans of a variety of X-rays, ranging from frontal chest projections and lumbar spine views to X-rays of the pelvis and knee, Rho provides alerts of possible low BMD, according to 16 Bit.
Rho™, an artificial intelligence (AI) software that may facilitate bone loss detection through opportunistic screening of X-rays for low bone mineral density (BMD), recently garnered a De Novo classification from the FDA. (Images courtesy of 16 Bit.)
In a recently published study in the Journal of the American College of Radiology (JACR), researchers found that Rho demonstrated area under the receiver operating characteristic (AUROC) curves of 89 percent, 87 percent and 82 percent in three independent data sets for detecting low BMD.
“An opportunistic screening tool such as this opens a window for early prevention and intervention strategies to slow the rate of bone loss,” noted lead study author Alexander Bilbily, M.D., FRCPC, the co-founder and co-CEO of 16 Bit, and an assistant professor and director of the Augmented Precision Medicine Lab at Sunnybrook Health Sciences Centre in Toronto, and colleagues.
Recent Videos
Related Content
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025Article
In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for cases > CAD-RADS 4A.
